Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results

被引：0

作者：

Reckamp, K. L. ^{[1
]}

Gilman, P. ^{[2
]}

Halmos, B. ^{[3
]}

Jahanzeb, M. ^{[4
]}

McCann, J. ^{[5
]}

Paripati, H. ^{[6
]}

Seneviratne, L. C. ^{[7
]}

Wallace, J. A. ^{[8
]}

Rueter, B. ^{[9
]}

Esler, A. ^{[10
]}

Dowling, E. ^{[11
]}

Koczywas, M. ^{[12
]}

机构：

[1] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA

[2] Lankenau Med Ctr, Canc Ctr, Wynnewood, PA USA

[3] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Deerfield Beach, FL USA

[5] DAmour Ctr Canc Care, Baystate Reg Canc Program, Springfield, MA USA

[6] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA

[7] Los Angeles Canc Network, Los Angeles Hematol Oncol Med Grp, Los Angeles, CA USA

[8] UChicago Med Ingalls, Dept Hematol Oncol & Geriatr, Harvey, IL USA

[9] Boehringer Ingelheim Pharmaceut Inc, CMDA Oncol, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[10] Syneos Hlth, Stat, Raleigh, NC USA

[11] Boehringer Ingelheim Pharmaceut Inc, Study Management & Conduct, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[12] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1456P

引用

页码：527 / 527

页数：1

共 21 条